Pacific Growth Keeps 'Overweight' on Dyax

Analyst Thomas Dietz recommends investors buy shares ahead of a Phase I/II study announcement for the biotech's rare blood disorder treatment

Pacific Growth reiterates its over-weight rating on Dyax (DYAX ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.